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Abstract: Until now, there has been progress in the treatment of ovarian cancer, 
but ovarian carcinoma is still a cause of high mortality. Various factors have been 
known to be associated with a poor prognosis, such as the absence of symptoms, 
lack of an effective screening tool, diagnosis of the disease that was only detected 
after an advanced stage, high recurrence of disease resistant to chemotherapy. 
There are more than 70% of cases detected in advanced stage, with long-term 
survival of only 15-30%; while those detected in early stages, the survival reaches 
90%. The recurrence risk of IIIC stage disease is as high as 40% -50%. However, 
there is a small group of patients who can recover after standard therapy. There is 
variability in the recurrence-free period and survival, so it is difficult to predict the 
outcome with certainty. Ovarian cancer patients with the same characteristics can 
show a different prognosis, related to high molecular heterogeneity of tumor 
genetics. We report a rare case that is a 56-year-old woman who has experienced a 5-
year free disease after complete remission after standard chemotherapy from stage 
IIIC ovarian cancer. The disease-free period of up to 5 years after therapy may be 
related to factors that can be predictors of prognosis, such as age at diagnosis, body 
mass index, physical performance, cancer cell biology, and the success of surgical 
response and chemotherapy in these patients. 
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Abstrak: Telah terdapat kemajuan dalam pengobatan kanker ovarium, namun hingga saat 
ini karsinoma ovarium masih merupakan penyebab mortalitas yang tinggi. Berbagai faktor 
telah diketahui berkaitan dengan prognosis yang buruk, seperti tidak adanya gejala, 
kurangnya alat screning yang efektif, diagnosis penyakit yang baru terdeteksi setelah sta-dium 
lanjut, tingginya rekurensi penyakit yang resisten terhadap kemoterapi. Lebih dari 70% 
kasus datang dengan stadium lanjut, dengan kelangsungan hidup jangka panjang hanya 
15–30%; sementara yang terdeteksi pada stadium awal kelangsungan hidupnya mencapai 
90%. Risiko rekurensi penyakit stadium IIIC setinggi 40%-50%. Namun terda-pat 
sekelompok kecil pasien yang dapat sembuh setelah terapi standar. Terdapat variabili-tas 
masa bebas kekambuhan dan kelangsungan hidup sehingga sulit memprediksi hasil seca-ra 
pasti. Pasien kanker ovarium dengan karakteristik yang sama dapat menunjukkan prog-nosis 
yang berbeda, terkait dengan heterogenitas molekular genetika tumor yang tinggi. Berikut 
kami laporkan kasus yang jarang,  wanita 56 tahun yang telah mengalami masa bebas 
penyakit selama 5 tahun paska remisi komplit setelah kemoterapi standar dari kanker  
ovarium  stadium  IIIC.  Masa  bebas  penyakit   hingga  5  tahun   setelah  terapi 
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kemungkinan berkaitan dengan faktor yang dapat menjadi 
prediktor prognosis, seperti umur saat terdiagnosis, indeks 
massa tubuh, performa fisik, biologi sel kanker, serta keberha-
silan dari respon terapi pembedahan dan kemoterapi pada 
pasien tersebut. 
 
Kata Kunci: Kanker Ovarium; Faktor Prognosis; Masa 
Bebas Kekambuhan 
 
INTRODUCTION 
 
Although epidemiologically there have been 
significant developments in the successful manage-
ment of ovarian carcinomas, the mortality rate 
caused by the disease is still relatively high. The 
study conducted by Ezzati M. et al. (2014),1 revealed 
that this is thought to be caused by the condition of 
patients who are often diagnosed during the ad-
vanced phase, the lack of a method of weaning 
early disease, the initial condition of asymptomatic 
disease, as well as recurrence of disease that is 
resistant to chemotherapy. 
According to Ezzati M. et al. (2014),1 recurrence 
rate of ovarian carcinoma after complete remission 
after the first chemotherapy series can reach 40% -
50%, where it is very varied and gives a different 
prognosis even among individuals having similar 
clinical symptoms.  
Efforts to predict recurrence of ovarian car-
cinoma after complete remission is a challenge, due 
to the high molecular heterogeneity of the disease. 
Therefore, Zhang M. et al. (2015),2 stated studies 
related to biology of carcinoma cells may be able to 
predict therapeutic responsiveness and can help 
predict long-term Disease Free Survival (DFS) rates.  
The main treatment for ovarian cancer with 
radical cytoreduction surgery is then followed by 
adjuvant chemotherapy with a standard regimen of 
paclitaxel and carboplatin. The rate of response to 
chemotherapy with a median of progression-free 
survival (PFS) 15-18 months, and median of overall 
survival (OS) of less than 3 years. Platinum free 
interval is the most important factor in predicting 
patient response to second-line therapy, divided 
into platinum-refractory, platinum-resistant, plati-
num-sensitive partial, and sensitive platinum.3 
Here we report a fairly rare case, a 56-year-old 
woman who has experienced a disease-free period / 
Disease-free survival (DFS) for 5 years after com-
plete remission after standard chemotherapy from 
stage IIIC ovarian cancer. DFS that occurs in 
patients up to 5 years after therapy may be related 
to various factors that can be predictors of the 
patient's prognosis, such as age at diagnosis, body 
mass index, physical performance, biology of cancer 
cells, and the success of surgical response and 
chemotherapy in the patients. 
 
CASES 
 
A 56 years old woman, first came with 
complaints of abdominal pain in August 2012. 
Ultrasonography (USG) examination revealed a 
solid and cystic mass in the posterior uterus with a 
size of 7.5 cm x 7.0 cm. Ca 125 marker examination 
showed a result = 1867, with carcinoembryonic 
antigen (CEA) 0.85. The patient was then planned 
to undergo a Total Abdominal Hysterectomy (TAH), 
Bilateral Salpingo Oophorectomy (BSO) and de-
bulking to undergo a surgical staging procedure.   
Based on surgical staging accompanied by an 
examination of pathological tissue, a picture of 
multilocular ovarian cystadenocarcinoma of the 
papilliferum musinosum, with an image of adenocar
 
 
Figure 1. MSCT Patients with Recurrent Tumor Mass in Left Adnexa 
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-cinoma in ascitic fluid was obtained. The patient 
was later diagnosed with stage IIIC ovarian car-
cinoma. Postoperative examination of CA 125 mar-
kers reached 552. The patient then underwent che-
motherapy with regimen of paclitaxel 300 mg and 
450 mg carboplatin for 6 cycles at intervals of 21 
days. 
The patient completed chemotherapy tho-
roughly in December 2012. Post-chemotherapy eva-
luation with abdominal ultrasound results in the 
absence of an abdominal tumor mass, with a nor-
mal chest X-ray examination. The CA 125 post 
chemotherapy result was 5.54. The patient is then 
determined as Complete Remission of ovarian 
carcinoma. 
Quarterly monitoring in 2013 to 2014 did not 
find any symptoms and signs that lead to carcinoma 
recurrence. The six-month evaluation until 2016 
found no symptoms and signs that lead to carcino-
ma recurrence.  
In February 2017, the patient again complained 
of abdominal pain. An ultrasound examination 
found a tumor mass of 5.21 cm x 3.58 cm, further 
examination of multi-slice computed tomography 
(MSCT) of the abdomen found a cystic mass in the 
left adnexa with a size of 5 x 4 cm (Figure 1.). 
Examination of CA 125 markers obtained results 
31.4. Then, the patient is planned to undergo a de-
bulking procedure. Post debulking tissue pathology 
examination showed results in the form of cysta-
denoma papiliferum serosum. 
 
DISCUSSION 
 
Based on the Canadian Cancer Society, there 
are several factors which determine the prognosis 
dan survival and possible recurrence of ovarian 
carcinoma. 4 
Table 2. explained several prognostic factors 
such as stadium carcinoma, carcinoma cell findings 
in peritoneal fluid, the spread of intra-abdominal 
tumor CA-125 marker concentration, obesity, age of 
physical performance, tumor type, responsiveness 
to chemotherapy, immunological factors, and the 
molecular profile of carcinoma cells.5 
Carcinoma stadium when the diagnosed 
happened is the most important determinant factor 
which determines the prognosis of the disease. 
Early carcinoma provides a better prognosis when 
compared  to  the  advanced  stadium.  According to 
Ezzati M. et al. (2014),1  related  to the  prognosis of 
ovarian carcinoma, concluded that stadium IA 
ovarian carcinoma having a survival rate in 5 years 
reached 94% while stadium IV having a survival rate 
in 5 years reached 18%. In this patient, the stadium 
at the time of diagnosis was stadium III C which  has  
Table 1. Survival of Ovarian Cancer Patients 
Stadium 5-year survival 
I 90% 
IA 94% 
IB 92% 
IC 85% 
II 70% 
IIA 78% 
IIB 73% 
IIC 57% 
III 39% 
IIIA 59% 
IIIB 52% 
IIIC 39% 
IV 17% 
(Canadian Cancer Statistics, 2017)4 
 
a prognosis of survival rate in 5 years reaching 39%.1 
According to Ezzati M. et al. (2014),1 the 
presence of carcinoma cells in ascites or perito-
neum washing results indicates a worse prognosis 
compared to the absence of carcinoma cell. In this 
patient, ascites formation was found, with ascitic 
fluid cytology analysis showing the presence of 
carcinoma cells suggestive of adenocarcinoma. 
Ezzati M. et al. (2014),1 explain the spread of 
carcinoma cells to the abdominal and pelvic wall 
associated with a worse prognosis compared to the 
absence of the proliferation of carcinoma cells. In 
this patient, tumor cell infiltration was found in the 
post-DFS pelvis for five years. The process can occur 
as a result of the metastasis process or as a result of 
a process called Ovarian Remnant Syndrome (ORS), 
which occurs as a result of excision of the income-
plete from ovarian carcinoma tissue. According to 
Imai A, Matsunami K, Takagi H et al. (2014),6 inci-
dence of ORS generally occurs within a median of 
12-13 years (range of 2-54 years). The way to 
differentiate postoperative pelvic/abdominal tumor 
lesions/chemotherapy ovarian carcinoma is to use 
tissue histology and FSH concentration. FSH con-
centrations < 40 mIU/ml in patients who got the 
BSO procedure can lead to the diagnosis of ORS (In 
this patient, post-debulking histological tissue 
examination for the indications of the finding of 
tumor cell infiltration on the pelvis produced a 
result in the form of cystadenoma serosum 
papiliferum).6 
The examination of grade tumor also helps in 
knowing the prognosis of patients with ovarian 
carcinoma as a result of this examination, which 
reflects on the biology of the tumor cells. According 
to Ezzati M. et al. (2014),1 high-grade tumor tend to 
have a worse prognosis compared to low-grade 
tumors. In this patient, no further analysis was 
carried out related to the degree of differentiation
 | 71 
 
Table 2. Prognostic Factors of Ovarian Carcinoma 
Determinant factor Conditions with a good prognosis 
Carcinoma Stadium Early Stadium 
Findings and Spread of Carcinoma cell There are no carcinoma cell findings in ascites and abdominal 
spread 
Grade tumor Low-grade tumor 
Debulking Optimal debulking 
Concentration of CA-125 Decreased CA-125 concentration after chemotherapy 
Obesity, age, physical performance No obesity, young, good physical performance 
Chemotherapy response Complete remission 
Carcinoma cell subtype Endometrioid and musinosum 
Immunological factors Tumor infiltrating lymphocytes findings 
Molecular profile  XRCC1 deficiency 
 homologous recombinant deficiency 
 The Increase of expressions of Her2, KRAS and EGFR 
 The decrease of expressions of BRCA1 and BRAF  
(Landrum L.M., et al., 2013)5 
 
of tumor cells. 
Ezzati M. et al. (2014),1 explained the results of 
effective therapy from the debulking process also 
influence the prognosis of patients with ovarian 
carcinoma. Patients with optimal debulking had a 
significantly higher survival rate compared to the 
group of patients with suboptimal debulking. Fur-
thermore, the size of the remaining tumor cells in 
the group of patients who got suboptimal de-
bulking also influences the patient's prognosis. 
Residual lesions of <0.5 cm have a survival rate of 
up to 56 months, while residual lesions of > 0.5 cm 
have a survival rate of up to 27 months (P <.001).1 
The success of debulking (optimal/suboptimal) can 
also be predicted by the expression of the p53 
gene, where tumors that express that gene tend to 
be difficult to achieve the optimal debulking of 
patients who have undergone the optimal de-
bulking operative procedure.7 
Decreased concentrations of CA-125, according 
to Ezzati M. et al. (2014),1 has significant prognostic 
value. The decrease in CA-125 concentration after 
chemotherapy showed excellent responsiveness to 
chemotherapy and be a marker of a better prog-
nosis compared to without changes in CA-125 level 
after therapeutic action. In this case report, the 
patient experienced a significant decrease in CA-125 
concentration after surgery and chemotherapy.1 
Obesity also affects prognosis in patients with 
ovarian carcinoma. Some related studies are Diaz 
ES, Karlan BY, Li AJ. (2013).8 They concluded that 
the risk relative to the aspect of mortality obtained 
results in the form of 1.5 times higher mortality risk 
in ovarian carcinoma patients with a body mass 
index above 35 kg/m2 compared to the group of 
patients with a healthy body mass index. These 
findings are thought to be related to overex-
pression of the hormone leptin, where leptin is 
known to increase the progression of some types of 
carcinomas. In this patient, obesity was not found. 
The age factors also have a significant effect 
on the prognosis and recurrence rate of ovarian 
carcinoma. The ovarian carcinoma that occurs at 
the age of fewer than 65 years is associated with a 
median survival time that can reach two years 
longer, has a good level of tumor cell differentia-
tion, and is less invasive when compared to ovarian 
carcinoma that occurs over the age of 65 years. 
Also, research conducted by Ezzati M., et al. (2014),1 
revealed ovarian carcinoma that occurred at age > 
65 years associated with more comorbid diseases 
and more reduced physical performance. In this pa-
tient, the diagnosis of the patient's ovarian carcino-
ma is established at the age of 56 years.1 
Ezzati M. et al. (2014),1 explains the status of 
physical performance in patients with ovarian carci-
noma adopting the physical performance assess-
ment system from the Eastern Cooperative Onco-
logy Group/World Health Organization. The assess-
ment was carried out by dividing the patient's phy-
sical performance into five classification assess-
ments, i.e., 0: asymptomatic, 1: symptomatic but 
can complete outpatient therapy, 2: symptomatic, 
spend < 50% in bed during the day, 3: symptomatic, 
ordain activity > 50% in bed during the day, and 4: 
spend the whole activity in bed. Patients with poor 
physical performance are associated with more 
inadequate therapeutic responses and more sub-
stantial side effects than those in the group of pa-
tients who have functional performance status. This 
patient has the performance status of equivalent to 
the value of 1 calibration. 
According to Ezzati M. et al. (2014),1 respon-
siveness from chemotherapy is related to the prog-
nosis of the patient. The complete therapeutic res-
ponse after first cycle chemotherapy is associated 
with a good prognosis. The patient reaches com-
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plete remission after chemotherapy. This result indi-
cates the responsiveness of treatment is adequate 
and represents a good prognosis. 
The histological type of carcinoma cells in 
ovarian carcinomas can represent the prognosis of 
the disease. This study shows that every kind of 
histological picture of carcinoma cells correlates 
with different prognoses. For example, research 
conducted by Prat J. (2012),9 that high-grade serous 
tumors have a poor prognosis, whereas the type of 
musinosum is associated with a good prognosis. 
Nevertheless, the type of musinosum has a reason-
ably low prevalence, which is 2-4% of all cases of 
ovarian carcinoma, with the majority of cases (90%) 
from the type of musinosum which have tumor cell 
types of low differentiation (low-grade tumor). This 
finding is related to a good prognosis, relatively 
small mortality with a five years survival rate that 
can reach 90%. Nevertheless, cases of recurrence or 
metastasis of the type of musinosum are associated 
with a poor prognosis and the possibility of 
metastases occurring in unexpected places such as 
the bones or lungs.10 In this patient, the type of car-
cinoma cell that appears is the type of mucinosum. 
In addition, patients also experience recurrence of 
cases of the type of musinosum. 
The existence of intratumoral lymphocyte T 
cell findings is a marker of immune cell sensitivity to 
resistant cell growth, which is a marker of a good 
prognosis. Patients with intra-tumoral lymphocyte T 
cells have an Overall Survival (OS) value that reach-
es 2.8 times greater and a Growth Free Survival 
(PFS) that reaches 3.9 times greater than the con-
trol. It also seems to be related to the optimization 
status of the debulking operative action, where the 
presence of lymphocyte T cell infiltration combined 
with the optimal operative work is associated with a 
good prognosis (Figure 2. & Figure 3.).11 In this case 
report, the patient was not examined for intratu-
moral T lymphocyte infiltration. 
 
 
Figure 2. Overall survival values of ovarian carcinomas with and without T cell lymphocyte infiltration and 
its relation to the optimization of debulking 
 
 
(Zhang L, et al., 2003)11 
Figure 3. Progress Free Survival Value of Ovarian Carcinoma with and without Clilocyte T Cell Infiltration 
and its Relation to Debulking Optimization 
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A series of examinations of carcinoma gene 
profiles can be used to determine the prognosis of 
ovarian carcinoma, where the biology of carcinoma 
cell DNA that is damaged after chemotherapy/ 
radiotherapy can be a marker of the prognosis of 
ovarian carcinoma. According to Ezzati M. et al. 
(2014),1 it was found that (X-ray repair cross-
complementing gene 1 (XRCC1) plays a vital role in 
the process of DNA repair after chemotherapy/-
radiotherapy. The deficiency of expression of these 
genes is a marker of an excellent therapeutic 
prognosis. Other studies have also found that some 
gene expression such as increased expression of 
Her2, KRAS, EGFR and decreased expression of the 
BRCA1 and BRAF genes are associated with a good 
prognosis. In this case report, the patient was not 
examined for gene profiles then, the impact on 
disease recurrence is unknown.1 
 
CONCLUSION 
 
Various determinants are known to help know 
the prognosis of ovarian carcinoma. Some of these 
factors include age, obesity, distribution of cancer 
cells in the pelvic/intra-abdominal cavity, optimiza-
tion of debulking, decreased CA-125 concentration 
after chemotherapy, physical performance, type 
and differentiation of carcinoma cells, intratumoral 
lymphocyte T cell infiltration, and various specific 
gene profiles. In this patient, multiple factors were 
found and were associated with good prognosis 
and long-term DFS including complete debulking, 
decreased CA-125 concentration after chemo-
therapy, age <65 years, no obesity, the excellent 
physical performance achieved remission complete 
post-chemotherapy and histopathological subtypes 
of the musinosum. Another parameter that can be 
done to determine the prognosis and predictors of 
long-term DFS with cost and easy access to do is by 
checking the intratumoral lymphocyte T cell 
infiltration. 
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